We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bid obviously has been lowered in the back, however it has not prompted any volume so looks like most PIs are looking past this to FDA decision which is expected to be positive. So perhaps a good opportunity for one final top up. Interesting interview on investor channel on expected decision https://www.youtube.com/watch?v=d-5IgpviOy8
Do hope this comes good for long suffering PIs here. All the best.
In parallel, a further longstanding institutional shareholder in ImmuPharma was approached to gauge their interest in participating in the current funding round. They too indicated their agreement in participating alongside Lanstead.
If anyone wants to buy shares on the cheap they can just phone SCP and buy at 5p!!! Be interesting to see how many they manage to sell at 5p, what’s clear is Avion didn’t want any and that’s a concern and neither did institutional investors
14.7% dilution at a standard discount. Fully expected by most. Funds imm through key inflection stages. Anyone trying to exaggerate things is just trying to get your shares on the cheap. ATB :)
It sounds dodgy.
It’s a 21% discount! Avion would not participate, why not is my question as this is a big concern
It’s a 14.7% dilution. Keep things in perspective.
If death spiral finance at 5p was the only option it does not bode very well, I am stunned that Avion did not participate at 5p… if Avion decide to pull out it’s all over here and to me something about this placing stinks, the broker option at 5p puts a floor on the share price at 5p, as does the 56m options and 30m warrants, so now we have a floor of 5p and two Lanstead death spiral agreements, fantastic
A 14.7% dilution to get us through the next 12 months.. “Assuming the Broker Option is fully subscribed, the Lanstead Subscription, (including the Lanstead Value Payment Shares), the Placing and the Broker Option combined would result in the issue, in aggregate, of 49,218,182 new Ordinary Shares, representing approximately 14.7 per cent of the Company's issued ordinary share capital as enlarged by the Lanstead Subscription (including the Lanstead Value Payment shares), the Placing and the Broker Option.”
Investor Presentation on 4th Aug 2022 at 12:00pm BST, Click below to register.
https://investormeetcompany.com/immupharma-plc/register-investor
Should hopefully settle some nerves and clarify.
I do hope that someone asks why if a recent research note by Stanford Capital Partners said we should be 37p (before trials) and with positive results we should be at 70p+ thereafter a placing was then done at 5p, which was a c. 60% discount to the placing in December.
Something stinks here imo, why were Avion happy to participate in the last placing at 11p but not this current placing at 5p a 60% discount… doesn’t make any sense. They couldn’t attract Institutional money so had to again go to Lanstead death spiral who wanted the shares at 5p and 30m warrants, if Avion backed IMM 7 months ago at 11p why will they not back them again today at 5p? Got everything crossed that Avion do not pull out as that really would destroy IMM, be lucky to be at 1p let alone 5p if they pull out, perils of investing on Aim
Lambo
Welcome to Tim McCarthy but hopefully Art Deas will take control after the FDA decision
Chairman Tim has effectively given away the company for buttons
56m free options at 5p and 30m free warrants too! Absolute disgrace
When most companies look for funding most of the time shareholders get shafted from companies like Lanstead unfortunately. To get the Funds comes at a price. Lets hope for positive news at end of month thank goodness Avion are involved otherwise imm would not have a future always do the talk but not the walk.
Final thoughts
The opening tomorrow will reveal what the Market thinks of the whole shenanigans.
ATB
Nota
If I was cynical I might think Chairman Mao Tse Tim was looking after a few old City mates before the FDA decision.
The FDA decision could make Lanstead and the "other " private investor a fortune and nobody would invest now at any price unless the decision was near 100% certain.
We will never know but a potential 300% gain in 1/2 months attracted a few sharks.
IMHO always
Difficult to understand the 21% discount here, when the last placing was at a premium at 11p. A bit difficult to understand as well the urgency of the need and why they could not await just one further month when the FDA decision on Stage 3 is expected by the 29th. It would be helpful if TM could spell out the investment potential here otherwise confetti shares from placings will continue to scare off potential investors.
K3
The only consolation is that if Art Deas hadn't come onboard and agreed to fund the Phase3 Lupuzor trial to the tune of $25m and invest £1.2m at 11p in the last placing together with submitting the application to the FDA something the Alora Pharma Group is highly experienced in
Immupharma would be in liquidation now and we would all have lost everything.
Small mercies I agree but we are still in the game and 15/20p is not out of the question if we get a favourable FDA decision.
That’s a very thorough shafting of PIs.
Remind me to stay the fxxk away from anything that has Lanstead written on it.
Lambo,
You were spot on regarding the fund raise but I should not have been
surprised after 5/6 years stuck in IMMU.
However, the punters must be confident of a successful FDA outcome to invest
more in the company because if the decision is negative then they will lose
everything like the rest of us.
Hang on to your seats for what promises to be a scary ride.
Well there it is, death spiral funding with Lanstead at 5p and £1.3m to be raised with private investors or HNW via the broker again at 5p… holders really have been screwed here, 25% discounted placing and more for Lanstead to sell too
Well thats that out way think everyone expected some kind of raise. Now for defining moment FDA go ahead on Lupzur, mentioned before about hopeful progress in other areas but these seem to get a mention from time to time without getting any further forward. So looks like it all rests on Lupzur and Avion
Well, Lambo was right about the cash shortage.
It is now all about the FDA decision and Uncle Tim is chucking in another £60,000
so he must be very confident.
Lanstead is set to clean up here for no real risk if FDA gives the go-ahead.
Fingers crossed
but when I was in this stock for 3 years up till 2 months ago I thought the last cash call in Autumn 01 was meant to see them through till 03?
Not only a placing but a huge amount of warrants & options set at around 5p which will limit any potential upside for shareholders